论文部分内容阅读
目的检测苯巴比妥癫癎患者血浆型血小板活化因子乙酰水解酶(PAF-AH)活性,了解苯巴比妥抗癫癎治疗对免疫功能的影响。方法采用ELISA法测定16例单药PB抗癫癎治疗未发作EP患者,14例单药PB抗癫癎治疗发作患者及16例健康对照组的血浆型PAF-AH活性。结果癫癎未发作组、癫癎发作组和健康对照组血浆型PAF-AH活性分别为(15.91±1.59)、(17.66±1.46)(、15.52±1.18)nmol/(min.μl),发作组血浆型PAF-AH活性高于健康对照组(P<0.01),未发作组与对照组无显著差异(P>0.05)。结论单药苯巴比妥抗癫癎治疗EP患者发作后血浆型PAF-AH活性升高,可能是机体的一种自我保护措施。
Objective To detect plasma platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with phenobarbital epilepsy and investigate the effect of phenobarbital antiepileptic treatment on immune function. Methods Plasma PAF-AH activity was measured by ELISA in 16 untreated EP patients treated with monotherapy with PB anti-epilepsy, 14 patients treated with monotherapy with PB anti-epilepsy and 16 healthy controls. Results The plasma PAF-AH activity in the epileptic seizure group, epileptic seizure group and healthy control group were (15.91 ± 1.59), (17.66 ± 1.46), (15.52 ± 1.18) nmol / (min.μl) The activity of PAF-AH in plasma was higher than that in healthy controls (P <0.01), but there was no significant difference between untreated and control groups (P> 0.05). Conclusion The anti-epilepsy phenobarbital treatment of EP patients after the onset of plasma-type PAF-AH activity may be the body’s a self-protection measures.